LGALS1 and hepatocellular carcinoma: Recently, Carabias and coworkers used the human hepatocellular carcinoma (HCC), HepG2/C3A (CRL-10741, a clonal derivative of the HepG2 cell line), and PLC/PRF/5 cell lines to successfully demonstrate that galectin-1 (a β-galactoside-binding protein abundantly expressed in the tumor microenvironment, highlighted as a hallmark of hepatocellular carcinoma’s progression, aggressiveness, and metastasis given its potential involvement in chemoresistance) protects these cell lines from doxorubicin- and sorafenib-induced cell death.